期刊
EXPERIMENTAL EYE RESEARCH
卷 72, 期 3, 页码 341-350出版社
ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD
DOI: 10.1006/exer.2000.0957
关键词
autoimmune disease; experimental autoimmune uveoretinitis; immunopathology; immunomodulation; uveitis; monoclonal antibody; in vivo animal models
资金
- Multiple Sclerosis Society [541] Funding Source: Medline
Experimental autoimmune uveoretinitis (EAU) can be induced in the B1O.RIII mice following immunization with bovine interphotoreceptor retinoid binding protein (IRBP) and human IRBP161-180 peptide. This study examines the value of the human IRBP161-180 peptide model in the B1O.RIII mice. as a suitable model of EAU in order to examine immunotherapies, Having established a reliable and consistent immunization protocol of 25 mug peptide and no PTX, the time course of histopathology was performed. which graded both cellular and structural scores individually. Disease was typically of an acute nature. characterized by rapid onset of a massive inflammatory response. resulting in extensive damage to the rod outer segments (ROS) and neuronal layers. Treatment with potent immuno suppressive agents. CD4-specific monoclonal antibodies resulted in the inhibition of disease and a reduction in disease incidence. Treatment with p55-tumor necrosis factor receptor-Ig (p55-TNFR-Ig) fusion protein reduced structural damage to the retina despite a high level of cellular infiltration in the eye, suggesting that target organ damage in an acute model of EAU can be modulated. (C) 2001 Academic Press.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据